JPRN-UMIN000026154已完成未知
The contribution of gut microbiome to liver carcinogenesis after SVR - Gut microbiome and liver carcinogenesis after SVR
agasaki University Hospital0 个研究点目标入组 60 人开始时间: 2017年2月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with some diffuse lesions in large colon. 2. Patients with severe general complications 3. Patients who were judged to be inappropriate for this study.
研究者
相似试验
招募中
不适用
The role of microbiota in liver diseasesK83.9K83.0K83.1K83.8K87.0Obstruction of bile ductOther specified diseases of biliary tractDisease of biliary tract, unspecifiedDisorders of gallbladder and biliary tract in diseases classified elsewhereCholangitisDRKS00010513Medizinische Hochschule Hannover350
尚未招募
不适用
The role of the gut microbiome in the pathogenesis of IgA nephropathyglomerulonephritisNL-OMON49937Radboud Universitair Medisch Centrum150
已完成
不适用
Compositional Shift of Gut Microbiome According to the Complications in Patients With Liver CirrhosisLiver CirrhosisNCT05786755Chuncheon Sacred Heart Hospital3,000
招募中
不适用
The analysis of gut microbiome pre- and post-liver transplantatioJPRN-UMIN000026133agasaki University Hospital50
进行中（未招募）
1 期
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blind Phase II trial (FLORA)MedDRA version: 21.0Level: LLTClassification code: 10019828Term: Hepatocellular carcinoma non-resectable Class: 10029104Hepatocellular carcinomaCTIS2023-506887-15-00niversitaetsklinikum Heidelberg AöR48